Method of examining allergic disease
OwnerNoriko Ohtani, Keiko Matsui +3inventors
InventorsNoriko Ohtani, Keiko Matsui, Nei Yoshida, Yuji Sugita, Kenji Izuhara
Life of this patent
Estimating the term…
Abstract
Six genes, whose expressions were greatly changed in a plurality of cells by stimulating respiratory tract epithelial cells with IL-4 or IL-13, were obtained as allergy related genes. This invention provides a method of testing for allergic diseases, and method of screening for compounds useful in treating such diseases, that use as indicators, expression levels of these genes in biological samples.
Claims17
A method of testing for an allergic disease, the method comprising the steps of:
- a) measuring the expression level of one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1 in a biological sample from a subject, and
- b) comparing the expression level measured in (a) with that in a biological sample from a normal healthy subject.
A reagent for testing for an allergic disease, said reagent comprising an oligonucleotide that is at least 15 nucleotides long and that has a nucleotide sequence complementary to a polynucleotide having a nucleotide sequence of one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1 or to a complementary strand of the polynucleotide.
A reagent for testing for an allergic disease, said reagent comprising an antibody that recognizes a peptide having an amino acid sequence of one or more proteins selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1.
A method of screening for a therapeutic agent for an allergic disease, the method comprising the steps of:
- (1) contacting a candidate compound with a cell that expresses one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1, and/or one or more genes functionally equivalent thereto,
- (2) measuring the expression level of the one or more genes, and
- (3) selecting a compound that lowers the expression level, compared to a control.
A method of screening for a therapeutic agent for an allergic disease, the method comprising the steps of:
- (1) administering a candidate compound to a test animal, (2) measuring, in a biological sample from the test animal, the expression level of one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1, and/or one or more genes functionally equivalent thereto, and
- (3) selecting a compound that lowers the expression level of the one or more genes, compared to a control.
A method of screening for a therapeutic agent for an allergic disease, the method comprising the steps of:
- (1) contacting a candidate substance with a cell transfected with a vector having a transcription regulatory region of one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1, and/or one or more genes functionally equivalent thereto, and a reporter gene that is expressed under the control of the transcription regulatory region,
- (2) measuring activity of the reporter gene, and
- (3) selecting a compound that lowers the expression level of the reporter gene, compared to a control.
A method of screening for a therapeutic agent for an allergic disease, the method comprising the steps of:
- (1) contacting a candidate substance with one or more proteins selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1, and/or one or more proteins functionally equivalent thereto,
- (2) measuring activity of the one or more proteins, and
- (3) selecting a compound that lowers the activity, compared to a control.
A therapeutic agent for an allergic disease, said agent comprising, as a major component, an antisense DNA against one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1 or against a portion thereof.
A therapeutic agent for an allergic disease, said agent comprising, as a major component, an antibody that binds to one or more proteins selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1.
Use of a transgenic non-human vertebrate in which the expression level of one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96, and CYP1B1, and/or one or more genes functionally equivalent thereto is elevated in respiratory tract epithelial cells, as an animal model for an allergic disease.
A kit for screening for a candidate compound for a therapeutic agent for an allergic disease, the kit comprising
- a polynucleotide that is at least 15 nucleotides long and that hybridizes to a nucleotide sequence of one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96(MAP17), and CYP1B1 or to a complementary sequence thereof, and
- a cell that expresses a gene comprising a nucleotide sequence of one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96(MAP17), and CYP1B1.
A kit for screening for a candidate compound for a therapeutic agent for an allergic disease, the kit comprising
- an antibody that recognizes a peptide having an amino acid sequence of one or more proteins selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96(MAP17), and CYP1B1, and
- a cell that expresses a gene comprising a nucleotide sequence of one or more genes selected from the group consisting of carboxypeptidase M, cathepsin C, endothelin-A receptor, osteoblast specific factor 2, DD96(MAP17), and CYP1B1.
Dependencies are inferred from the claim text.